INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines

Pomerantz LLP filed a securities class action against ARS Pharmaceuticals alleging potential securities fraud and unlawful business practices, with investors eligible to seek lead-plaintiff status by October 5, 2026. The case follows ARS's June 24 disclosure that CVS Caremark delayed a decision on expanded neffy insurance coverage until January 2027, missing the summer and back-to-school allergy seasons. ARS shares fell $2.52, or 23.91%, to $8.02 on June 25 following the disclosure.

Analysis

The relevant investable issue is not the lawsuit itself—plaintiff-firm announcements rarely alter enterprise value—but the payer-access delay it highlights. For SPRY, the missing back-to-school selling window likely shifts revenue recognition and raises the probability that sales-force, marketing, and manufacturing costs are absorbed against a materially lower 2026 revenue base; that creates disproportionate cash-burn and potential financing risk for a single-product commercial-stage biotech. The January 2027 CVS Caremark decision is therefore both a reimbursement catalyst and a binary validation of management’s access assumptions.

Near term, additional law-firm notices and lead-plaintiff deadlines can sustain retail-driven pressure but should not independently justify a position. Over the next 1-3 months, the key read-through is formulary breadth beyond CVS, prescription growth versus the company’s implied launch trajectory, and whether management cuts commercial spend or reiterates cash runway. A favorable CVS decision in January may restore distribution, but it cannot recover the missed seasonal demand period; the market should discount any claim that coverage alone restores 2026/early-2027 growth.

CVS has immaterial direct earnings exposure, but its formulary decision underscores payer leverage over branded rescue-medicine launches. The more meaningful competitive dynamic is that delayed reimbursement preserves incumbent injectable epinephrine utilization and reduces the near-term value of SPRY’s differentiation; this increases the hurdle for SPRY to demonstrate that convenience converts to durable paid prescriptions rather than samples or cash-pay demand. Contrarian upside exists only if broad non-CVS coverage already supports prescriptions sufficiently to make the CVS delay a timing issue rather than evidence of weak pharmacoeconomic acceptance.

Key Decisions for Investors

• Avoid treating the litigation announcement as a standalone SPRY short catalyst; it is largely non-fundamental and the post-disclosure price reset has already occurred. Reassess after the next earnings release for prescription trends, net price, commercial spend, and updated cash runway.
• Maintain a bearish SPRY watch bias into the next results if management maintains prior revenue ambitions without a commensurate reduction in operating expense. A downside position is actionable only if reported paid-script growth and non-CVS formulary wins fail to offset the lost seasonal channel; cover on evidence of accelerating paid prescriptions or a broad payer-access win.
• For event-driven mandates, consider a small defined-risk SPRY put structure spanning the next earnings date rather than naked short exposure; commercial-stage biotech borrow, short interest, and a January access decision can create sharp squeezes. Size for a total premium loss if access data improve.
• Do not position in CVS on this development: the financial impact is de minimis relative to its PBM and insurance earnings base. Monitor CVS formulary decisions only as an industry signal for reimbursement standards facing other specialty and branded pharmaceutical launches.